T-cell reactivity during tapering of immunosuppression to low-dose monotherapy prednisolone in HLA-identical living-related renal transplant recipients

Transplantation

Volumn 87, Issue 6, 2009, Pages 907-914

  Gerrits, Jeroen H ^a   Van De Wetering, Jacqueline ^a   Weimar, Willem ^a   Van Besouw, Nicole M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Dendritic cells; Immunosuppression; Minor histocompatibility antigens; Renal transplantation; T cell reactivity

Indexed keywords

AZATHIOPRINE; CYTOKINE; GAMMA INTERFERON; GRANZYME B; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; DRUG DERIVATIVE; GRANZYME; HLA ANTIGEN; MYCOPHENOLIC ACID; TETANUS TOXOID;

ADULT; ARTICLE; BLOOD SAMPLING; CELL MATURATION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MONOTHERAPY; PRIORITY JOURNAL; STEROID THERAPY; T LYMPHOCYTE; CHILD; DRUG ADMINISTRATION; FAMILY; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; REOPERATION;

ADULT; AZATHIOPRINE; CHILD; DRUG ADMINISTRATION SCHEDULE; FAMILY; FEMALE; GRANZYMES; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; REOPERATION; T-LYMPHOCYTES; TETANUS TOXOID; YOUNG ADULT;

EID: 65549111267     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819b3df2     Document Type: Article

References (57)

1. Gerrits JH, Weimar W, Van Besouw NM. Immune monitoring after kidney transplantation. Minerva Urol Nefrol 2007; 59: 367.
2. Goulmy E. Minor histocompatibility antigens: From transplantation problems to therapy of cancer. Hum Immunol 2006; 67: 433.
3. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 1570.
4. Joosten SA, van Kooten C. Non-HLA humoral immunity and chronic kidney-graft loss. Lancet 2005; 365: 1522.
5. Heinold A, Opelz G, Scherer S, et al. Role of minor histocompatibility antigens in renal transplantation. Am J Transplant 2008; 8: 95.
6. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
7. Soulillou JP, Giral M. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001; 72(12 suppl): S89.
8. van Besouw NM, Vaessen LMB, Zuijderwijk JM, et al. The frequency of interferon- producing cells reflects alloreactivity against minor histocompatibility antigens. Transplantation 2003; 75: 1400.
9. Gerrits JH, van de Wetering J, Postma S, et al. Stable T-cell reactivity after successful tapering of azathioprine in HLA-identical living-related kidney transplant recipients despite minor histocompatibility antigen mismatches. Nephrol Dial Transplant 2007; 22: 353.
10. Gerrits JH, van de Wetering J, IJzermans JNM, et al. Granzyme B ELISPOT assay determines the cytotoxic T lymphocyte precursor frequency after HLA-identical living-related kidney transplantation. Transplant Proc 2005; 37: 752.
11. Beik AI, Higgins RM, Lam FT, et al. Steroid withdrawal and donorspecific hyporeactivity after cadaveric renal allotransplantation on maintenance triple therapy. Nephrol Dial Transplant 1997; 12: 1949.
12. Creemers P, Pascoe MD, Pontin AR, et al. Rebound effect of the allogenic T-cell response to donor and third-party lymphocytes after cyclosporine withdrawal in renal transplant recipients. Transpl Immunol 1998; 6: 261.
13. Goulmy E, Bittner K, Blokland E, et al. Renal transplant patients with steroid withdrawal evaluated longitudinally for their donor-specific cytotoxic T cell reactivity. Transplantation 1991; 52: 1083.
14. Mazariegos GV, Ramos H, Shapiro R, et al. Weaning of immunosuppression in long-term recipients of living related renal transplants: A preliminary study. Transplant Proc 1995; 27: 207.
15. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353.
16. Brouard S, Dupont A, Giral M, et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant 2005; 5: 330.
17. Louis S, Braudeau C, Giral M, et al. Contrasting CD25hiCD4-T cells/ FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81: 398.
18. Roussey-Kesler G, Giral M, Moreau A, et al. Clinical operational tolerance after kidney transplantation. Am J Transplant 2006; 6: 736.
19. Strober S, Benike C, Krishnaswamy S, et al. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: Studies of chimerism and anti-donor reactivity. Transplantation 2000; 69: 1549.
20. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000; 106: 145.
21. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000; 165: 6037.
22. Mazariegos GV, Sindhi R, Thomson AW, et al. Clinical tolerance following liver transplantation: Long term results and future prospects. Transpl Immunol 2007; 17: 114.
23. Mazariegos GV, Zahorchak AF, Reyes J, et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 2003; 3: 689.
24. Penna G, Sozzani S, Adorini L. Cutting edge: Selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol 2001; 167: 1862.
25. Kuwana M, Kaburaki J, Wright TM, et al. Induction of antigen-specific human CD4(-) T cell anergy by peripheral blood DC2 precursors. Eur J Immunol 2001; 31: 2547.
26. Sallusto F, Schaerli P, Loetscher P, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998; 28: 2760.
27. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245.
28. Hackstein H, Thomson AW. Dendritic cells: Emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004; 4: 24.
29. Athanassopoulos P, Vaessen LMB, Maat AP, et al. Preferential depletion of blood myeloid dendritic cells during acute cardiac allograft rejection under controlled immunosuppression.AmJ Transplant 2005; 5(4 Pt 1): 810.
30. Hackstein H, Renner FC, Bohnert A, et al. Dendritic cell deficiency in the blood of kidney transplant patients on long-term immunosuppression: Results of a prospective matched-cohort study. Am J Transplant 2005; 5: 2945.
31. Hesselink DA, Vaessen LMB, Hop WC, et al. The effects of renal transplantation on circulating dendritic cells. Clin Exp Immunol 2005; 140: 384.
32. Mazariegos GV, Zahorchak AF, Reyes J, et al. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant 2005; 5: 314.
33. Sordi V, Bianchi G, Buracchi C, et al. Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: Selective upregulation by rapamycin. Transplantation 2006; 82: 826.
34. Baan CC, Weimar W. Intragraft cytokine gene expression: Implications for clinical transplantation. Transpl Int 1998; 11: 169.
35. Le Moine A, Goldman M, Abramowicz D. Multiple pathways to allograft rejection. Transplantation 2002; 73: 1373.
36. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002; 2: 735.
37. Ouwehand AJ, Baan CC, Roelen DL, et al. The detection of cytotoxic T cells with high-affinity receptors for donor antigens in the transplanted heart as a prognostic factor for graft rejection. Transplantation 1993; 56: 1223.
38. Van de Wetering, Gerrits JH, van Besouw NM, et al. Successful tapering of immunosuppression to low dose monotherapy steroids after livingrelated HLA identical renal transplantation. Transplantation (in press).
39. Gerrits JH, Wetering J, Drabbels JJ, et al. Donor-reactive cytokine profiles after HLA-identical living-related kidney transplantation. Nephrol Dial Transplant 2008; 23: 2016.
40. Gerrits JH, Athanassopoulos P, Vaessen LMB, et al. Peripheral blood manipulation significantly affects the result of dendritic cell monitoring. Transpl Immunol 2007; 17: 169.
41. Hricik DE, Heeger PS. Minimization of immunosuppression in kidney transplantation. The need for immune monitoring. Transplantation 2001; 72(8 suppl): S32.
42. de Lathouder S, Gerards AH, de Groot ER, et al. Mycophenolic acid and methotrexate inhibit lymphocyte cytokine production via different mechanisms. Eur Cytokine Netw 2002; 13: 317.
43. Jonsson CA, Carlsten H. Mycophenolic acid inhibits inosine 5- monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. Int Immunopharmacol 2003; 3: 31.
44. Kaminska D, Tyran B, Mazanowska O, et al. Mycophenolate mofetil but not the type of calcineurin inhibitor (cyclosporine vs tacrolimus) influences the intragraft mRNA expression of cytokines in human kidney allograft biopsies by in situ RT-PCR analysis. Transplant Proc 2005; 37: 770.
45. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683.
46. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007; 7: 585.
47. Cai J, Lee J, Jankowska-Gan E, et al. Minor H antigen HA-1-specific regulator and effector CD8- T cells, and HA-1 microchimerism, in allograft tolerance. J Exp Med 2004; 199: 1017.
48. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7: 610.
49. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769.
50. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002; 99: 351.
51. Ehser S, Chuang JJ, Kleist C, et al. Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: Promises and difficulties. Hum Immunol 2008; 69: 165.
52. Solari MG, Thomson AW. Human dendritic cells and transplant outcome. Transplantation 2008; 85: 1513.
53. Mehling A, Grabbe S, Voskort M, et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000; 165: 2374.
54. Colic M, Stojic-Vukanic Z, Pavlovic B, et al. Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol 2003; 134: 63.
55. Liu HN, Wong CK. In vitro immunosuppressive effects of methotrexate and azathioprine on Langerhans cells. Arch Dermatol Res 1997; 289: 94.
56. Lagaraine C, Lebranchu Y. Effects of immunosuppressive drugs on dendritic cells and tolerance induction. Transplantation 2003; 75(9 suppl): 37S.
57. Blanco P, Palucka AK, Pascual V, et al. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008; 19: 41.